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Objectives The purpose of this study was to evaluate the feasibility, safety, and outcomes of radiofrequency ablation of
atrial fibrillation (AF) in patients with mechanical mitral valve replacement (MVR).
Background The role of ablative therapy in patients with MVR is not yet established, with safety concerns and very few outcome data.
Methods Between January 2003 and December 2008, we followed up 81 patients with MVR undergoing first-time AF ab-
lation (compared with 162 age- and sex-matched controls). Arrhythmia recurrences were identified by symptoms
with documentation, event monitoring, Holter monitoring, and electrocardiograms.
Results All MVR and control patients underwent ablation under therapeutic international normalized ratio. No entrap-
ment of catheters or stroke occurred. There were no differences in terms of procedure-related complications be-
tween the groups (p  NS). Patients with MVR had larger atria (p  0.0001), lower left ventricular ejection frac-
tions (p  0.0001), and more concomitant atrial flutter at baseline (p  0.0001). Over a 24-month follow-up,
they had higher recurrence rates compared with controls (49.4% vs. 27.7% after a single ablation, p  0.0006).
The creation of flutter lines significantly reduced recurrences in patients with any history of atrial flutter (16.7%
vs. 60.9%, p  0.009). At last follow-up, 82.7% of MVR patients had their arrhythmia controlled (69.1% not re-
ceiving antiarrhythmic drugs).
Conclusions Radiofrequency ablation is feasible and safe for patients with MVR. It allowed restoration of sinus rhythm in a
substantial proportion of patients undergoing ablation. An abnormal atrial substrate underlies recurrences in
these patients. The ablation procedure needs to be further refined with a focus on extra pulmonary vein triggers
and concomitant flutters to improve outcomes. (J Am Coll Cardiol 2011;58:596–602) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.039Atrial fibrillation (AF), the most common cardiac arrhyth-
mia, frequently complicates the course of mitral valve
disease (1,2). Among patients undergoing mitral valve
replacement (MVR), many have AF, and in many others,
AF and atrial flutter (AFL) develop after their surgery. It is
not uncommon that AF becomes resistant to medical
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accepted March 21, 2011.management in patients with MVR, and these patients are
referred for radiofrequency ablation.
Pulmonary vein isolation (PVI) and ablation of left atrial
flutter are effective treatments for drug resistant atrial arrhyth-
mias (3). The role of ablative therapy in patients with mechan-
ical MVR is not yet established, with very few data in the
literature on feasibility, safety, and outcomes (4,5). In this
distinct group of patients, the procedure carries a risk of
prosthetic valvular damage and entrapment of the ablation
catheter within the prosthesis, necessitating open-heart sur-
gery. Furthermore, patients with MVR have a particular atrial
substrate of their arrhythmia with surgical scarring, fibrosis
around the mitral annulus (MA), and probable atrial myopathy
from chronic mitral valve disease. An abnormal atrial substrate
may potentially contribute to arrhythmia recurrences in these
patients. We aimed to evaluate the feasibility, safety, and
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MVR.
Methods
Ablation protocol. Our PVI and periprocedural anticoag-
ulation protocols have been described in details (6,7).
Briefly, all antiarrhythmic drugs were stopped 4 to 5
half-lives before ablation, with the exception of amiodarone,
which was stopped a minimum of 4 to 5 months before the
procedure. Warfarin was continued at a therapeutic inter-
national normalized ratio (INR) level at time of ablation. A
transesophageal echocardiogram was obtained for patients
presenting in AF if they had a subtherapeutic INR within 3
weeks before ablation to exclude a left atrium (LA) append-
age thrombus. Light to moderate sedation was used during
the procedure. For cardioversion, deep sedation was used
briefly; otherwise, deep sedation was avoided to allow
monitoring for neurologic complications.
A 10-F 64-element phased-array intravascular ultrasound
catheter (Siemens AG, Malvern, Pennsylvania) was used for
intracardiac echocardiography (ICE) imaging during the
procedure. The ICE catheter was positioned in the right
atrium (RA) and rotated clockwise to obtain the standard
trans-septal view. In all patients, ICE was used to assist with
trans-septal punctures, to define pulmonary vein (PV)
anatomy, and most importantly in this particular group of
patients, to obtain direct views of the LA and monitor for
complications including pericardial effusion or damage to
native or prosthetic valves. The ICE catheter remained in
the RA for the entire duration of the procedure. For all
mapping and ablations near the prosthetic valves, continu-
ous real-time ICE imaging and frequent fluoroscopy checks
were used to accurately localize the catheters relative to the
prosthetic valves to prevent entrapment. The electrocardio-
graphic tracing screens were also monitored for any artifacts
that may result from the catheters being close to the metallic
valves, but every effort is made to avoid any contact of the
catheters with the valves.
After trans-septal puncture, the activated clotting time
was maintained in the range of 350 to 450 s. Two catheters
were advanced into the LA for mapping and ablation guided
by ICE. All PVs were isolated in all patients under ICE
guidance.
The cornerstone for ablation was PVI, including ablation
of the antrum encompassing most of the posterior wall.
Electrical isolation was confirmed with absence of PV
potentials along the antrum or inside the veins by use of a
circular mapping catheter. At the discretion of the operator,
further ablation was performed along the septum. For
patients in AF, ablation in the coronary sinus or base of the
appendage was considered. When a non-PV trigger was
identified during the procedure, this was also targeted. For
patients in sinus rhythm (SR), the endpoint of the proce-
dure was PVI. For patients in AF, PVI and restoration of
SR was an endpoint for ablation. For patients in whomanother tachycardia developed
during the procedure, the ar-
rhythmia was mapped and ab-
lated with SR restoration as an
endpoint. For patients with a
history of AFL, attempts to in-
duce the arrhythmia were made
in almost all patients, and this
was mapped and ablated with SR
restoration as an endpoint. For
patients in whom we failed to
restore SR by ablation, cardio-
version was performed. For all
patients, when a non-PV trigger
was identified after restoring SR,
this was targeted by ablation.
The superior vena cava (SVC)
was mapped in all patients, and
potentials were ablated when
there was no phrenic nerve stim-
ulation.
In patients with typical AFL,
ablation of the cavotricuspid
isthmus (CTI) was performed. For atypical flutters, the
critical isthmus of the arrhythmia was defined by electro-
anatomic activation mapping and by entrainment. Ablation
was then performed to transect the identified isthmus. The
endpoint of flutter ablation was its termination, demonstra-
tion of bidirectional block across the isthmus, and nonin-
ducibility of AFL by right and left atrial rapid and pro-
grammed pacing without drug use and then after
isoproterenol infusion (up to 20 g/min). Mitral block was
determined by pacing maneuvers described by the Bordeaux
group (8,9). Roof block was confirmed by pacing from the
appendage and by demonstrating low to high activation in
the posterior wall. Patients were monitored for complica-
tions during the procedure and their overnight hospital stay.
We defined as major complication any complication that
results in death, prolongation of hospital course, or requires
an intervention. Otherwise, complications were considered
minor.
Study population and follow-up. Between January 2003
and December 2008, all patients with MVR referred to our
electrophysiology laboratory for first-time AF ablation were
included. For each patient with MVR, we identified 2 age-
and sex-matched patients from our AF ablation database
who underwent PVI during the same period. When multi-
ple matches were available, we selected as controls the
ablations performed by the same operator on the case during
the same period (priority given to controls closer in time to
cases). All cases and controls had failed at least 2 antiar-
rhythmic drugs plus a negative dromotropic agent. A
24-month follow-up was considered for the study popula-
tion (with additional 24 months after last ablation in
patients with repeat ablation). Clinical data were collected
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follow-ups were scheduled for patients who experienced
symptoms, arrhythmia recurrence, or complications from
the procedure. All patients had transthoracic echocardio-
grams within 3 months before ablation and after PVI to
assess for procedure-related mechanical valve dysfunction.
After ablation, all patients were given an event recorder to
monitor for arrhythmias during the first 3 months, and
recorded on a weekly basis and whenever symptomatic.
Additional event recorder monitoring was obtained beyond
the 3-month period in patients with arrhythmia or symp-
toms consistent with arrhythmia within the first 3 months.
Patients had 24-h Holter recordings at 3, 6, 12, and 24
months after ablation. Arrhythmia recurrence was identified
if an atrial tachyarrhythmia, lasting 30 s or more, was
captured on a 12-lead electrocardiogram, event recording, or
Holter monitor. Atrial arrhythmias occurring during the
first 2 months after PVI (blanking period) were not counted
as recurrences. Antiarrhythmics were used in the first 2
months after ablation then stopped, unless continued ar-
rhythmia mandated their use. Amiodarone was never used
after ablation. All success rates were determined off antiar-
rhythmic drugs.
Statistical analysis. Results are presented as percentages
for categorical variables and mean  SD for continuous
variables. Nonnormally distributed variables are presented
as median (interquartile range [IQR]). The matching pro-
cess for age and sex aimed to minimize the impact of
noncardiovascular confounders. For subsequent analyses,
the cases and controls were compared as independent
samples to highlight the anatomical differences between the
groups and their clinical implications. Clinical characteris-
tics were compared by the Student t test or Wilcoxon
rank-sum test for continuous variables as appropriate. For
categorical variables, the chi-square test or Fisher exact test
was used as appropriate. Kaplan-Meier survival curves were
used to present arrhythmia-free survival after ablation (dif-
ferences between the groups tested by using the log-rank
test). Cox proportional hazards analyses were employed to
assess for factors associated with arrhythmia recurrence in
patients with MVR. A 2-sided p value 0.05 was consid-
ered statistically significant. All statistical analyses were
performed with SPSS software (version 15.0, SPSS, Chi-
cago, Illinois).
Results
Population characteristics. The study included 81 patients
with MVR and 162 age- and sex-matched controls. Their
baseline characteristics are summarized in Table 1. The
indications for MVR were mitral regurgitation (MR) in
52.5% of patients, mitral stenosis (MS) in 5%, both
MR/MS in 11.3%, rheumatic valvular disease in 25%,
congenital mitral disease in 2.5%, and unknown in 3.8%.
They had their valve prostheses for a median of 6 years
(IQR: 2 to 10 years; minimum and maximum: 1 and 36 (years) before ablation, and 28 of them (34.6%) had a maze
procedure (10 radiofrequency, 8 cryothermal, 4 “cut and
sew,” 6 unknown) at time of their initial surgery.
Compared to controls, Patients with MVR were more
likely to have hypertension (p  0.01) but as likely to have
diabetes mellitus or coronary disease (pNS). In the MVR
group, 29.6% of patients underwent ablation for nonparox-
ysmal AF compared with 32.7% of patients in the control
group (p  0.62). The arrhythmia duration before ablation
was also similar in the groups (6 [IQR: 3 to 8] years vs. 5
[IQR: 3 to 7] years, p  0.61). Importantly, concomitant
AFLs were more frequent in patients with MVR (43.2% vs.
14.8%, p  0.0001). Patients with MVR had lower left
ventricular ejection fractions (p 0.0001) and larger atria (p
 0.0001) compared with controls. The INRs on day of the
procedure were similar in both groups (2.47  0.6 vs. 2.62
 0.8, p  0.82).
Radiofrequency ablation data. All MVR patients and
controls underwent isolation of all 4 PVs. The SVC
potentials were found and ablated more frequently in
patients without MVR (84.7% vs. 64.2%, p  0.002). More
atients in the MVR group required ablation in the coro-
ary sinus (24.7% vs. 14.2%, p  0.04). The ablation
rocedures were longer (154  23 min vs. 123  19 min,
 0.03) and required more fluoroscopy (37  12 min vs.
7  8 min, p  0.01) in patients with MVR.
At time of ablation, 27 of 81 (33.3%) patients with MVR
resented in AF, 16 (19.8%) presented in AFL, 1 (1.2%) in
trial tachycardia (AT), and 37 (45.7%) in SR. Of 37
atients presenting in SR, 11 patients (29.7%) had AF
uring the procedure (terminated by ablation in 8, by
ardioversion in 3). For those who presented with atrial
achyarrhythmia, ablation was performed in the presenting
hythm in 37 patients (AF terminated by ablation in 30 and
y cardioversion in 7) and after cardioversion in 7 patients
SR maintained for the total duration of the procedure).
In addition to PVI and SVC ablation in patients with
VR, LA triggers were found and ablated in 36 patients
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Parameter
No MVR
(n  162)
MVR
(n  81) p Value
Age, yrs 56.9 11.5 56.2 11.2
Female 55.9 55.6
Hypertension 29.7 41.9 0.01
Diabetes mellitus 7.9 7.4 0.88
Coronary disease 14.9 14.7 0.91
Nonparoxysmal AF 32.7 29.6 0.62
Concomitant AFL 14.8 43.2 0.0001
Concomitant AT 3.1 4.9 0.12
AF duration, yrs 6 (3–8) 5 (3–7) 0.61
LVEF, % 54.5 8.5 49.2 10.6 0.0001
LAS, cm2 23.1 5.4 30.3 8.0 0.0001
AF atrial fibrillation; AFL atrial flutter; AT atrial tachycardia; LAS left atrial size; LVEF left
ventricular ejection fraction; MVR  mitral valve replacement.44.4%). Additional targeted areas included the septum in
pulmon
o
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MA in 13 patients (16.0%), and RA/crista in 26 patients
(32.1%), in addition to flutter ablation lines in patients with
concomitant AFLs (Table 2).
To note that AFL were more commonly encountered in
patients with prior maze (67.9%, vs. 30.8% in patients
without maze, p  0.0013). Moreover, 27 of 28 patients
with prior maze (96.4%) were found to have conduction
recovery around the lines encircling the PVs.
Among patients with MVR and history of concomitant
flutters (35 patients, 43.2%), 16 (45.7%) presented in SR, 2
(5.7%) in AF, 1 (2.9%) in AT, and 16 (45.7%) in AFL.
During catheter manipulation in the atria and by isoproter-
enol induction (in 2 patients), 9 more patients (25.7%) had
AFL. Overall, 25 patients (71.4%) either presented in AFL
or had AFL during the procedure, but electroanatomic
mapping of AFLs was performed in 22 of them. In the
remaining 3, flutters occurred during ablation but self-
terminated in 2 and during PVI in 1 of them. No further
mapping of the flutters was performed, and all 3 had empiric
CTI ablation.
Of 22 patients who underwent flutter mapping, 6 had RA
flutters (3 CTI flutters terminated with CTI ablation, 3
incisional flutters), 5 had LA flutters (all with prior maze),
and 11 had both RA and LA flutters (7 with prior maze).
Of 5 patients with LA flutters, 2 had MA flutters
(terminated with ablation in the left lateral atrial wall close
to the MA in 1 of them, by cardioversion after failure of
multiple flutter lines “MA to left inferior and right superior
PVs, lines in roof, septum and posterior wall” to terminate).
The remaining 3 patients with LA flutters had macro
Electrophysiologic Findings on 22 Patients With Mitral Valve ProstTable 2 Electrophysiologic Findings on 22 Patients With Mitra
6 patients with right AFLs
3 CTI flutters All 3 with CTI ab
3 RA incisional flutters Line connecting
Line connecting
with focal abl
Line connecting
5 patients with left AFLs
2 MA flutters Ablation at LA la
Multiple lines in
3 macro–re-entry around PVs PVI in 1 patient,
11 patients with both RA and LA flutters
8 CTI flutters
2 CTI  LA roof flutter CTI ablation  le
1 CTI  MA flutter CTI ablation  le
1 CTI  LA anterior septum AFL CTI ablation  le
1 CTI  RA incisional flutter and left-side flutter CTI ablation  li
during ablatio
3 CTI  multiple re-entrant circuits in both RA and LA CTI ablation plus
3 without CTI flutter had multiple re-entrant circuits Multiple flutter li
CTI  cavotricuspid isthmus; LA  left atrium; MA  mitral annulus; PV  pulmonary vein; PVI 
ther abbreviations as in Table 1.re-entry around the PVs (terminated with PVI in 1, roofline in 1, and cardioversion after failure of multiple lines to
terminate the flutter in 1).
Of 11 patients with both RA and LA flutters, 8 had a CTI
dependent flutter successfully ablated in all of them. Two of
them had a LA roof flutter (terminated with LA roof line), 1
had a MA flutter (Fig. 1) terminated with a line from MA to
right inferior PV, 1 had an anterior septum flutter (terminated
with anterior septal line), 1 had an RA incisional flutter and a
LA flutter (after CTI ablation, an RA incisional flutter was
s and Concomitant AFLe Prostheses and Concomitant AFL
Mode of AFL Termination
l scar to the SVC
l scar to the SVC to TCL prolongation to spontaneous conversion to AT; terminated
o high crista terminalis
l scar to tricuspid annulus
all close to MA
CL prolongation but not termination; cardioverted to sinus rhythm
roof ablation line in 2 patients
terminated with LA roof line
terminated with line from MA to RIPV
terminated with anterior septal line
RA scar to SVC to PVI to AFL spontaneously converted to a slow AT; terminated
e carina region
le empiric flutter lines did not terminate; cardioverted to sinus rhythm
not terminate; cardioverted to sinus rhythm
ary vein isolation; RA  right atrium; SVC  superior vena cava; TCL  tachycardia cycle length;
Figure 1 Map of Counter-Clockwise Perimitral Flutter
Inferior anterior view of NAVX (St. Jude Medical, Minneapolis, Minnesota) map
of a counter-clockwise perimitral flutter. CSR  catheter in coronary sinus;
LI  left inferior pulmonary vein; LS  left superior pulmonary vein; MV  mitral
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the scar; during PVI, the flutter spontaneously converted to a
slow AT that terminated during ablation of the carina region
of the left PVs). The remaining 3 patients had multiple
re-entrant circuits in both RA and LA (multiple empiric lines
failed to terminate, and both patients had PVI and then
cardioverted to SR). Of 11 patients with both RA and LA
flutters, 3 did not have CTI flutters. All had multiple re-
entrant circuits with failure of flutter lines to restore SR. All
were cardioverted after successful PVI.
Overall, AFLs were terminated by ablation in 15 of 22
patients in whom electroanatomic mapping was performed
(68.2%).
Clinical outcomes. All but 3 patients with MVR (3.7%)
and 7 patients without MVR (4.3%) completed the study
follow-up. All 10 patients with incomplete follow-up had
recurrence requiring repeat ablations in 2008 and 2009. All
had at least 12 months of follow-ups after their last ablation,
with recurrence of AF in 1 patient with MVR and 2 patients
without MVR. These patients were accounted for in the
overall analysis of recurrence and success rates.
Patients with MVR had more recurrences than controls
(49.4% vs. 27.8%, p  0.0006). The recurrent arrhythmia
as more likely to be AFL (54.8% vs. 40%) or AT (2.4% vs.
%) and less likely to be AF (59.6% vs. 93.3%) in patients
ith MVR (p  0.04). The clinical characteristics and
chocardiographic and ablation data according to arrhyth-
ia recurrence in patients with MVR are summarized in
able 3. Patients with arrhythmia recurrence had older
rostheses in place (time since MVR 7 [3 to 12] years vs. 4
2 to 8] years, p  0.03) and were more likely to have had
F for longer duration (7 [4 to 10] years vs. 5 [2 to 8] years,
 0.04). In univariate Cox proportional hazards analyses,
actors found to have a significant association with arrhyth-
ia recurrences were time since MVR (hazard ratio for 1
ear change: 1.04, 95% confidence interval: 1.01 to 1.12,
 0.04) and longer duration of AF before ablation (hazard
atio for 1 year change: 1.03, 95% confidence interval:
.01 to 1.09, p  0.05). There was a significant decrease in
A size in patients with MVR at 3 months after ablation
mean difference3.6 cm2, standard error 0.7, p 0.0001),
ut this change in atrial size did not predict ablation
utcomes (hazard ratio for 1 cm2 change: 0.58, 95%
confidence interval: 0.12 to 2.71, p  0.49).
Among patients with a history of AFL, those who
underwent mapping of their flutters with subsequent abla-
tion had lower recurrence rates compared with patients who
did not have flutter mapping and ablation (16.7% vs. 60.9%,
p  0.009). Of 7 patients with failure of ablation to
terminate the flutters and subsequent cardioversion to SR,
all 3 patients in whom ablation resulted in prolongation of
the tachycardia cycle length remained arrhythmia free
whereas the remaining 4 patients had recurrence.
There was a trend toward better outcomes in patients
having prior maze compared with patients not having prior
maze (recurrence rate 39.3% vs. 55.8%, p  0.16). Therecurrent arrhythmia were more likely to be AFL or AT in
patients with prior maze (AFL 63.7% vs. 51.6%; AT 9.1%
vs. 0%; p  0.04).
Repeat ablations and outcomes at last follow-up. Of pa-
tients with arrhythmia recurrence, 29 patients with MVR
(72.5%, 24 with 2 ablations, 5 with 3 ablations) and 33 patients
without MVR (73.3%, 26 with 2 ablations, 7 with 3 ablations)
had repeat ablations. All repeat ablations were performed in
the presenting rhythm. Overall, more ablations per person
were required in MVR patients (1.4  0.6 vs. 1.2  0.5, p 
0.003) but failed to achieve similar success rates at last
follow-up (69.1% vs. 87.0%, p 0.0006). The arrhythmia-free
survival in patients with and without MVR after single or
repeat ablations is outlined in Figure 2. At last follow-up, of 81
patients with MVR, 56 (69.1%) were arrhythmia free while not
taking antiarrhythmic drugs, 11 (13.6%) had their arrhythmia
controlled with antiarrhythmic drugs that had previously failed,
and 14 (17.3%) had drug-resistant AF and were managed with
rate control.
Procedure-related complications. Three patients in the
MVR group had procedure-related complications (3.7%; 1 he-
matoma requiring intervention, 1 groin bleeding requiring
transfusion, 1 femoral pseudoaneurysm requiring surgical re-
Clinical Characteristics, EchocardiographicData, and Ablation Data A c rding toArrhythmia Re ur ence in Patients With MVR
Table 3
Clinical Ch ra teristics, Echo ardiographic
Data, and Ablation Data According to
Arrhythmia Recurrence in Patients With MVR
Parameter No Recurrence Recurrence p Value
n (%) 41 (50.6) 40 (49.4)
Age, yrs 55.8 10.6 56.5 11.8 0.78
Female 46.3 65 0.09
Hypertension 56.1 47.5 0.44
Diabetes mellitus 9.8 5 0.41
Coronary disease 12.2 17.5 0.11
Time since MVR, yrs 4 (2–8) 7 (3–12) 0.03
Prior maze 42.5 25 0.14
Indication for MVR 0.5
MR 55 50
MS 2.5 7.5
MR/MS 12.5 10
Rheumatic MS 25 25
Congenital 0 5
Unknown 5 2.5
Nonparoxysmal AF 26.8 32.5 0.58
Concomitant AFL 46.3 40 0.56
Concomitant AT 4.9 5 0.98
AF duration, yrs 5 (2–8) 7 (4–10) 0.04
AF before MVR 53.7 47.5 0.58
4 PVs isolated 100 100 1.0
Left atrial triggers 48.8 40 0.43
Right atrial triggers 26.8 37.5 0.3
SVC ablation 58.5 70 0.28
LVEF, % 49.3 11.3 49.2 10.1 0.96
LAS, cm2 29.8 8.4 30.7 7.7 0.64
Values are n (%), mean  SD, %, or median (range).
MR  mitral regurgitation; MS  mitral stenosis; MVR  mitral valve regurgitation; other
bbreviations as in Tables 1 and 2.pair). No patients with MVR had stroke, cardiac tamponade,
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within the prosthesis. The incidence of procedure related
complications were similar in both groups (Table 4).
Discussion
This is the largest study to date to evaluate the feasibility,
safety, and outcomes of AF ablation in patients with MVR.
We have demonstrated that the procedure is feasible and is
not associated with increased risk of complications, partic-
ularly no catheter entrapment occurred. An average of 1.5
ablations per patient was required to restore SR off antiar-
rhythmic drugs in 70% of patients with MVR referred for
ablation. Also, ablative therapy allowed arrhythmia control
with medications that have previously failed in an additional
13% of patients. Only 17% continued to have drug-resistant
AF. In a group of patients who have failed medical
management, this may still be considered a clinical success.
Figure 2 Kaplan-Meier Curves for
Arrhythmia-Free Survival After AF Ablation
Kaplan-Meier curves for arrhythmia-free survival after atrial fibrillation (AF) abla-
tion in patients with mitral valve replacement (MVR) (blue lines) and without
MVR (red lines). (A) Arrhythmia-free survival after a single ablation. (B) Arrhythmia-
free survival after the last ablation (1.4  0.6 vs. 1.2  0.5 ablations per per-
son in patients with and without MVR). *Log-rank test p value.However, the overall success rates of radiofrequency abla-tion were lower in patients with MVR compared to con-
trols. Recurrent arrhythmias were more likely to be AFL or
AT and less likely to be AF in patients with MVR, and
occurred more frequently in patients with older prostheses
in place and in those with longer duration of AF. A
substantial proportion of patients with MVR had concom-
itant AFL at baseline. Electroanatomic mapping with cre-
ation of flutter lines, in addition to CTI ablation, signifi-
cantly improved the outcomes in patients with any history of
AFL during their AF course. The majority of patients
having prior maze procedures were found to have conduc-
tion recovery in at least 1 of the PVs and were more likely
to have concomitant flutters at baseline and to have more
recurrences as AFL or AT after ablation compared to
patients without a prior maze procedure.
Ablative therapy is feasible in MVR patients but requires
longer fluoroscopy times (5) to prevent valvular damage or
entrapment of the ablation catheter by frequently checking
the position of the catheter during ablation. Furthermore,
longer fluoroscopy times during mapping allow detailed
reconstruction of LA anatomy and help to accurately
localize the MA. These measures ultimately result in reduc-
tion of complications risk, but careful manipulation of ablation
catheters in the LA remains essential to prevent them.
Previously reported complications in patients with MVR
undergoing ablation in the LA are prosthesis disk emboli-
zation as a result of trauma from ablation catheters (10),
transient ischemic attacks (5), and catheter entrapment
within the prosthetic valve (4). None of these complications
occurred in our study. Interestingly, no patients had throm-
boembolic complications.
We believe that performing ablation with ICE guidance
and under therapeutic INRs were 2 critical factors that
contributed to the safety of AF ablation in our patients.
Intracardiac echocardiography allowed direct visualization
of catheters in the LA and determined in real-time the
position of catheters relative to the prosthetic valves, which
helped along with fluoroscopy to prevent entrapment or
damage to MV prostheses. The thromboembolic risk is a
major concern in patients with prosthetic valves and is
further increased with catheter-based ablation in the LA. It
Procedure-Related Complications inatients With an Without Mecha ical MVRTable 4 Procedure-Related Complications inPatients With and Without Mechanical MVR
Parameter
No MVR
(n  162)
MVR
(n  81) p Value
Minor complications, % 0.20
Pericardial effusion, no intervention 1.2 0
Major complications, % 0.52
Bleeding requiring transfusion 0.6 1.2
Hematoma requiring intervention 1.2 1.2
Femoral pseudoaneurysm 0 1.2
Tamponade 0.6 0
Stroke 0 0
Native or prosthetic valve damage 0 0MVR  mitral valve replacement.
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warfarin discontinuation at time of ablation is a safe enough
strategy to prevent these complications. In our study,
warfarin was continued at therapeutic levels at time of
ablation and may have protected against thromboembolic
complications, but it is hard to draw any conclusions
regarding this issue given the sample size. Further research
will be needed to address these issues.
Lang et al. (5) reported their experience with catheter
ablation in patients with MVR and enlarged atria. In their
study, more procedure-related complications and more fre-
quent post-ablation AT occurred among patients with
MVR. Overall, success rates were similar in patients with or
without MVR in their report but lower than success rates of
surgical therapy for AF at time of MVR (10–12). Many
findings in our study explain the lower success rates in
patients with MVR. The observations that these patients
have larger atria and lower left ventricular ejection fractions
at baseline suggest that a more advanced structural heart
disease underlies higher recurrence rates. Furthermore, sur-
gical scarring and fibrosis, in addition to probable atrial
myopathy from long-standing valvular disease potentially
contribute to arrhythmia recurrences. An arrhythmogenic
substrate explains the higher recurrence rates, suggesting
that the role of PV triggers in initiating and maintaining AF
in these patients is less important than it is in the general
population of patients referred for AF ablation. Our ability
to restore and maintain SR off antiarrhythmic drugs in a
substantial proportion of patients with MVR undergoing
PVI suggest that the PVs may still serve as AF triggers in
these patients, but the findings suggest that modification of
the atrial substrate is essential to improve ablation outcomes
(4). In particular, the observations of more concomitant
AFL at baseline, particularly in patients having prior maze
surgery, and the findings of more recurrences as AFL and
AT after AF ablation in patients with MVR underscores the
importance of the atrial substrate of the arrhythmia. In fact,
surgical scarring, incomplete ablation lines (13), and fibrosis
around the prosthetic valve facilitate macro re-entrant
tachycardia.
For patients who present in AFL or have AFL during
ablation, electroanatomic mapping and ablation of these
flutters is of major importance to prevent recurrences. For
patients with a history of AFL but do not have the
arrhythmia during ablation, induction of their flutters may
be warranted to allow electroanatomic mapping and the
application of flutter lines where appropriate. Furthermore,
the creation of empiric flutter lines, especially in patients
with obvious surgical scarring, may help to improve the
ablation outcomes. It may be also reasonable to perform
CTI ablation in all MVR patients with any history of AFL
during their AF disease course, given the high prevalence of
CTI flutters in these patients and the ease with which CTI
flutters can be eliminated. All of these factors should be
considered during the ablation procedure in patients withany previously documented AFLs, given the high recurrence
rates and ultimately the need for repeat ablations, but
further research will be needed to address this issue.
Conclusions
We have demonstrated that radiofrequency ablation is
feasible and safe but technically challenging in patients with
mitral valve prostheses. It was possible to restore SR off
antiarrhythmic drugs in a substantial proportion of patients
with MVR referred for AF ablation, but it seems that the
ablation procedure needs to be further refined. In particular,
ablation strategies with a focus on the atrial substrate,
extra-PV triggers, and concomitant flutters may help to
improve ablation outcomes.
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